Key result
Immunotherapy for thymoma achieves ~53% response but is linked to severe immune myocarditis and mortality.
Why the study?
Immunotherapy presents management challenges regarding immune-related adverse events, and this study aims to examine the treatment of thymic epithelial tumor-associated immune myocarditis.
While immunotherapy shows efficacy in thymic epithelial tumors, it is associated with a significant risk of severe and potentially fatal immune-related adverse events such as fulminant myocarditis.
Requires vigilant cardiac monitoring during immunotherapy for thymic tumors; leaves open optimal selection and risk mitigation in prospective trials.
Background: Immunotherapy offers new hope for cancer patients but presents new medical challenges for healthcare workers in terms of the management of immune-related adverse events (irAEs). The clinical data of two patients with advanced thymoma (T) admitted to the Fujian Cancer Hospital who developed fulminant myocarditis after undergoing immunosuppressant therapy were analyzed retrospectively, and the relevant literature was reviewed. This study aims to examine treatment of thymic epithelial tumors (TETs)-associated immune myocarditis. Case Description: An online search was conducted to retrieve relevant full-text articles, and the selected articles were assessed. In total, 13 articles, comprising the data of 113 patients, were included in an analysis to evaluate the efficacy of immunotherapy. Of the 113 patients, 19 had T and 94 had thymic carcinoma (TC). Of the 19 patients with T, 10 (52.6%) achieved a partial response (PR), 8 (42.1%) had stable disease (SD), and 1 (5.3%) had progressive disease (PD). Of the 94 patients with TC, 1 (1.1%) achieved a complete response (CR), 20 (21.3%) achieved a PR, 51 (54.3%) had SD, and 22 (23.4%) had PD. Five articles reported that fulminant myocarditis developed in nine thymic epithelioma patients who were treated with immunosuppressive agents. Two TC patients who presented with fulminant myocarditis were treated with high-dose corticosteroid therapy and underwent pacemaker insertion; none of the patients died of immune myocardial toxicity. However, of the seven T patients who received high-dose corticosteroid therapy and immunoglobulin therapy, and underwent pacemaker implantation, three survived and four died. Conclusions: Immunotherapy has shown promising results in the treatment of patients with refractory or relapsed TETs. Due to their susceptibility to paraneoplastic autoimmunity, TET patients are at a higher risk of developing severe irAEs than patients with other types of cancer. Given the relatively high morbidity and mortality of irAEs, the administration of immune checkpoint inhibitors (ICIs) to treat TETs should be balanced against the clinical response and the precipitation of potentially severe irAEs.
No takes yet. Share an insight, caveat, or question.
Ye et al. (2024) conducted a review in Thymic epithelial tumors and immune checkpoint inhibitor myocarditis (n=115). Immune checkpoint inhibitors (ICIs) was evaluated on Efficacy of immunotherapy (response rates) and incidence of fulminant myocarditis. Immunotherapy for thymic epithelial tumors achieved partial response in 52.6% of thymoma and 21.3% of thymic carcinoma patients, but is associated with severe immune myocarditis and mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: